FormLyophilised:Centrifuge vial prior to opening. Reconstitute in sterile PBS containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. Please note that if you receive this product in liquid form it has already been reconstituted as described and no further reconstitution is necessary
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesELISA: Use at a concentration of 0.25 - 1 µg/ml. Allows the detection of at least 0.2 - 0.4 ng/well of recombinant human BAFF.
sELISA: Use at a concentration of 0.25 - 1 µg/ml. Allows the detection of at least 0.2 - 0.4 ng/well of recombinant human BAFF.
WB: Use at a concentration of 0.1 - 0.2 µg/ml. The detection limit for recombinant human BAFF is 1.5 --3.0 ng/lane, under either reducing or non-reducing conditions. Predicted molecular weight: 31 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionCytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B-and T-cell function and the regulation of humoral immunity. A third B-cell specific BAFF-receptor (BAFFR/BR3) promotes the survival of mature B-cells and the B-cell response.
Tissue specificityAbundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. Also found in the spleen, lymph node, bone marrow, T-cells and dendritic cells. A lower expression seen in placenta, heart, lung, fetal liver, thymus, and pancreas.
Sequence similaritiesBelongs to the tumor necrosis factor family.
Post-translational modificationsThe soluble form derives from the membrane form by proteolytic processing. N-glycosylated.